X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Atlanta—Emory University’s general counsel, Kent B. Alexander, sat at his computer recently and watched $80 million go into Emory’s account. Then $211 million. Then a few hundred million dollars more—for total of $540 million. The money was Emory’s take from selling royalty interests in a promising new HIV drug, Emtriva, and its offspring Truvada. Combined sales of the two drugs this year is projected at more than $400 million. “It was a fun day,” said Alexander. “It’s not every day you do a half-billion-dollar deal in any sector-much less the university sector.” But the ease with which the cash flowed into Emory’s account belies more than a decade of complex legal battling for the Atlanta university to establish its rights to Emtriva. Emory’s side of the deal involved five law firms, plus its in-house law department, and legal fees well in the millions, said Alexander. A record, and a boost Emory’s payout is considered the largest ever to an American university for intellectual property. Emory’s reputation got a boost, too. Emtriva and Truvada come in tablets that need to be taken only once a day-an improvement over the drug cocktails historically prescribed to manage HIV. This development is so important that a University of Virginia patent foundation lists it along with saccharin, rocket fuel and insulin as university inventions that have changed the world. Emory’s lead patent lawyer on the deal, Robert L. Baechtold of New York’s Fitzpatrick, Cella, Harper & Scinto, said it was one of the knottiest pieces of litigation he’s worked on in his 40-year career. “Because of the length of time and number of parties involved and the complexity of the chemistry at issue, it was one of the most complex [matters] that I’ve done. And I do a lot of them,” he said. What made the disputes even more complex, he said, was that they went “from the patent office to the courts and back to the patent office, then back to the courts.” In the deal, Emory sold the rights to a compound called FTC-which is used in Emtriva and Truvada-to biopharmaceutical maker Gilead Sciences Inc. and intellectual property investor Royalty Pharma for $525 million. The companies threw in an additional $15 million for the right to use Emory’s compound in hepatitis B research. The lawyers were needed to sort out who had the rights to FTC and another compound called 3TC, both of which Emory scientists Raymond F. Schinazi, Dennis C. Liotta and Woo-Baeg Choi claim to have invented. Sherry M. Knowles of Atlanta-based King & Spalding filed Emory’s patent applications for the compounds about 15 years ago. Knowles could not be reached, but according to Schinazi, the timing was critical. The FTC dispute involved a race to the patent office. Schinazi said BioChem Pharma, a Qu�bec drug company that later was acquired by Shire Pharmaceuticals Group PLC, had earlier filed an application for a similar family of chemical compounds-but omitted the one for FTC, which has fluorine. BioChem realized its mistake and filed an application for a similar compound with fluorine-but not until a week later, Schinazi said. Another dispute broke out over the rights of Burroughs Wellcome-later acquired by drug-maker Glaxo-to use FTC. In the early 1990s, Emory had licensed FTC to Burroughs Wellcome, and the drug-maker subsequently filed its own patent application to use FTC in drugs for hepatitis. Emory argued that it had already specified that FTC could be used for hepatitis before Burroughs Wellcome, now Glaxo, got the idea. A separate dispute Meanwhile, a separate dispute arose over who had the rights to 3TC, a compound similar to FTC and also used to make drugs for HIV. By the time Emory’s application for 3TC was approved in 1996, Glaxo had a similar drug on the market, said Baechtold. Emory sued Glaxo and BioChem Pharma for patent infringement, claiming that Emory scientists had invented 3TC, and the battle began. The case was filed by A. Stephens Clay and John S. Pratt of Kilpatrick Stockton in Atlanta. Baechtold’s firm, a patent litigation boutique, subsequently joined the litigation. Glaxo and BioChem Pharma countersued-and also named Schinazi individually in their suit, claiming that he had improperly gained secret information that he used to develop 3TC. This brought another lawyer into the mix-Marlan B. Wilbanks of Atlanta’s Harmon, Smith, Bridges & Wilbanks to defend Schinazi against the fraud allegations, which were later dropped. A civil litigator with whistleblower expertise, Wilbanks said he first worked with Schinazi when the scientist’s neighborhood association needed an attorney to represent a group of homeowners. Litigation spreads Alexander joined the fray in 2000, when he left King & Spalding to become Emory’s general counsel after the 1999 death of Joseph Crooks. At that point, he said, the litigation was everywhere. Patent prosecution for the compounds was happening all over the world, plus there was a major piece of litigation in Washington. Knowles, who handled the patent prosecution, was jetting all over the world in an effort to secure the patents to the compounds in various countries. “Sherry had more frequent flyer miles than anyone in Atlanta at the time,” Alexander said. Alexander consolidated the litigation in Atlanta in 2000 and, finally, he said, “All parties agreed that it was time to mediate.” Emory and the drug companies settled in 2001. In the deal they struck, Emory transferred its rights to 3TC to Glaxo and BioChem Pharma, and received a royalty interest. And Emory got back the rights to FTC, in exchange for royalty payments to the drug-makers. Since universities cannot engage in the manufacture of drugs, Emory licensed its compound to Triangle Pharmaceutical, a company created by Schinazi in which Emory and the scientists were shareholders. Triangle sold itself to Gilead in 2003 and the Food and Drug Administration approved Emtriva, the drug based on FTC, for use in HIV treatment in July of that year. Gilead combined Emtriva with a drug in its own stable to create Truvada, which the FDA approved for HIV treatment in 2004. “It’s extremely potent. There’s nothing like it,” said Schinazi, who said sales for Truvada are projected at $1.6 billion in 2006. Alexander engaged Washington-based Covington & Burling to negotiate the lump-sum royalty payment-one of the few firms in the country, he said, that handles what’s called the monetization of royalty streams. That deal has kept Alexander and Deputy GC Stephen D. Sencer busy all summer, with additional help from Emory’s chief technology officer, Mary Severson. Emory’s $540 million payment represents its royalty interests in Truvada and predecessor drug Emtriva, in which Emory has about a 20% stake, said Alexander, the Emory GC. Emtriva, the drug based on the work of the Emory scientists, makes up 40% of Truvada. Instead of receiving annual royalty payments until Emory’s patent on FTC expires, the university elected to cash out now, which gives it a substantial chunk of money to invest in further scientific research, Alexander said.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.